Table 2 Comparison of baseline cytokine and cytokine receptor concentrations between patients who experienced disease flare and those who remained in remission.

From: Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission

 

Flare ( +), n = 20

Flare (−), n = 14

p-value

IL-1β

0.032 (0–0.069)

0.051 (0–0.096)

0.39

IL-2

0.056 (0–0.13)

0.17 (0.075–0.30)

0.017

IL-6

0.52 (0.36–2.1)

0.67 (0.41–1.1)

0.73

IL-8

9.2 (6.1–19.6)

14.6 (8.3–20.3)

0.14

IL-10

0.24 (0.14–0.37)

0.26 (0.19–0.40)

0.58

IFNγ

6.3 (2.6–85.4)

7.9 (6.2–14.8)

0.55

TNF

1.9 (1.6–16.9)

4.1 (2.9–33.0)

0.086

GM-CSF

0.068 (0–0.11)

0.12 (0.021–0.31)

0.21

VEGF

12.6 (7.5–18.8)

14.7 (11.5–19.8)

0.29

sTNFR1

1336.5 (1014.6–2055.6)

1184.0 (914.7–1255.8)

0.064

sTNFR2

5701.3 (3720.3–108,451.6)

7017.3 (5457.9–218,396.5)

0.23

sIL-6R

39,382.3 (24,570.5–56,730.8)

47,576.3 (38,110.1–59,504.7)

0.32

  1. Values are median (interquartile range), pg/mL.
  2. IL interleukin, IFNγ interferon gamma, TNF tumour necrosis factor, GM-CSF Granulocyte–macrophage colony-stimulating factor, VEGF vascular endothelial growth factor, sTNFR1 soluble tumour necrosis factor receptor 1, sTNFR2 soluble tumour necrosis factor receptor 2, sIL-6R Soluble IL-6 receptor.
Back to article page